Lung Neoplasm Malignant Clinical Trials

8 recruitingLast updated: June 17, 2026

There are 8 actively recruiting lung neoplasm malignant clinical trials across 18 countries. Studies span Not Applicable, Phase 2, Phase 1. Top locations include Santiago, Region M. de Santiago, Chile, Barcelona, Spain, Athens, Attica, Greece. Updated daily from ClinicalTrials.gov.


Lung Neoplasm Malignant Trials at a Glance

8 actively recruiting trials for lung neoplasm malignant are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Santiago, Barcelona, and Athens. Lead sponsors running lung neoplasm malignant studies include Merck Sharp & Dohme LLC, Copenhagen University Hospital at Herlev, and Chuangzhen Chen.

Browse lung neoplasm malignant trials by phase

Treatments under study

About Lung Neoplasm Malignant Clinical Trials

Looking for clinical trials for Lung Neoplasm Malignant? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lung Neoplasm Malignant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lung Neoplasm Malignant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1Phase 2

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC190 enrolled21 locationsNCT07286149
Recruiting
Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled37 locationsNCT06788912
Recruiting
Not Applicable

Enhanced COPD Management in Suspected Lung Cancer Patients

Lung CarcinomaLung Cancer (Diagnosis)Pulmonary Cancer+8 more
Ditte Krag-Hansen280 enrolled1 locationNCT07543601
Recruiting
Not Applicable

Confocal Laser Endomicroscopy VERification

Lung CancerCarcinoma, Non-Small Cell LungLung Neoplasm Malignant+1 more
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)208 enrolled5 locationsNCT06079970
Recruiting
Not Applicable

Benefit of Spectral Information in Patients Suspected for Lung Cancer

Lung Neoplasm Malignant
Copenhagen University Hospital at Herlev1,000 enrolled1 locationNCT06440616
Recruiting
Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting
Not Applicable

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Lung Neoplasm Malignant
Ruijin Hospital20 enrolled1 locationNCT04973293
Recruiting

MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

Lung Neoplasm Malignant
European Institute of Oncology270 enrolled2 locationsNCT05974475